|
Los Angeles, JuLY 5, 2017 - Today, Stockwatchindex (SWI) announces that on June 19, 2017 it has added Nabriva Therapeutics AG (NBRV:NasdaqGS) to its Biotech "QuickPicks Portfolio", supported by SWI Research and strong initial buy recommendation by six major Third Party Analysts.
|
|
|
Nabriva Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections. The company is developing intravenous and oral formulations of lefamulin that is in Phase III clinical trials for the treatment of community-acquired bacterial pneumonia; and intends to develop lefamulin for additional indications other than pneumonia. It is also developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics AG in 2007. Nabriva Therapeutics AG was incorporated in 2005 and is headquartered in Vienna, Austria.
|
|
|
Nabriva was
trading at $9.12 at SWI initiation on June 19, 2017
Initial Buy Recommendations by Six Major Third Party Analysts
Price Target b is $16.37
|
|
|
If you want to follow all other companies that we cover with more in depth research reports, go to our research site at
www.swiresearch.com/report-index
to download the reports,
or visit
www.stockwatchindex.com
for up to date news on the covered companies.
Please feel free to
re-distribute the reports to your friends and colleagues.
|
|
|
Rainer Poertner - Chief Analyst
|
|
|
S
tockWatchIndex and SWI Research (SWI) are not registered investment advisers and the information provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided.
SWI has not been compensated for this report, but may hold or plan to acquire positions of every stock in this report for its portfolio a
nd reserves the right to buy or sell positions at its sole
discretion. The included information is subject to change without notice. Please visit
www.swiresearch.com/#!legal-ease/lmvw1
for a full text of our Disclaimer, Privacy policy and Terms of Use.
|
|
|
|
|
|
|
